Chulalongkorn University researchers develop AI to assess stroke risk
A research team from the Medicine and Engineering faculties of Chulalongkorn University in Thailand has come up with an AI-powered web app to assess patients’ risk of stroke caused by heart diseases.
The tool called AICute uses AI to analyse patient’s brain scans, together with their symptoms and partial history, and generate a report on their stroke risk within half an hour.
According to a press release, the technology has a 92%-94% accuracy after being tested on a database of 40,000 high-resolution x-ray images. It has also achieved “satisfactory” results in a trial at Chulalongkorn Memorial Hospital.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The research team is now proceeding to test AICute in a large group of real patients and to collect more test data outside of Chula Hospital. An improved version of the AI tool is also expected to come out in the middle of the year. In the future, AICute will be released as paid commercial software.
Additionally, the research team plans to develop an AI to detect strokes from other causes, incorporating more databases of x-ray images and angiography.
Remidio gets CE mark for diabetic retinopathy detection AI
Indian medical device company Remidio has received Europe’s CE mark for its AI tool for detecting referable diabetic retinopathy (DR).
The smartphone-based Medios AI is said to be the only smartphone-based algorithm for detecting referable DR that works offline. It does its screening based on the Remidio NM-FOP fundus camera within 10 seconds.
Given its portability, the AI technology can be deployed and scaled in primary care settings that require minimal expertise, according to Remidio.
The CE marking closely follows the approval of Medios AI by Singapore’s Health Sciences Authority.
Dr Axel Baur takes CEO role at Amplify Health
Amplify Health, the joint venture of the AIA Group and Discovery Limited, has announced the succession of its deputy CEO Dr Axel Baur to the CEO post.
Dr Baur joined the company in March last year, coming from a 26-year run at McKinsey & Co. where he led its Asia Healthcare practice and served as a senior partner in its Hong Kong office.
He succeeds Dr Jonathan Broomberg who will remain as a non-executive director of Amplify Health and resume his role as CEO of Vitality Health International and the global head of health insurance at Discovery Limited.
Source: Mobihealth News
